Theophylline 300 GDC


Tablets 60's
scheduling status
S2
registration number
33/10.2/0417
What Theophylline 300 GDC is and what it is used for
THEOPHYLLINE 300 GDC tablets are indicated for the treatment and prophylaxis of reversible bronchospasm associated with asthma, chronic bronchitis and emphysema.
dosage
Adults: One THEOPHYLLINE 300 GDC tablet orally twice daily (i.e. 12 hourly), to be increased gradually by intervals of 2 to 3 days, if tolerated, to two tablets twice daily (i.e. 12 hourly), if necessary. Children: 5 to 8 years: 24 mg/kg/24 hours 9 to 12 years: 20 mg/kg/24 hours S2 13 to 16 years: 18 mg/kg/24 hours The average maintenance dose is 14 mg/kg/day. However, the individual biotransformation varies and it is advisable to monitor theophylline therapy with serum assays of theophylline. THEOPHYLLINE 300 GDC tablets may be halved but should not be crushed or chewed. THEOPHYLLINE 300 GDC tablets are not recommended for administration to children under 2 years of age. For children taking THEOPHYLLINE 300 GDC tablets, NUELIN LIQUID may be considered as an alternative.
how to take
Adults: One THEOPHYLLINE 300 GDC tablet orally twice daily (i.e. 12 hourly), to be increased gradually by intervals of 2 to 3 days, if tolerated, to two tablets twice daily (i.e. 12 hourly), if necessary. Children: 5 to 8 years: 24 mg/kg/24 hours 9 to 12 years: 20 mg/kg/24 hours S2 13 to 16 years: 18 mg/kg/24 hours The average maintenance dose is 14 mg/kg/day. However, the individual biotransformation varies and it is advisable to monitor theophylline therapy with serum assays of theophylline. THEOPHYLLINE 300 GDC tablets may be halved but should not be crushed or chewed. THEOPHYLLINE 300 GDC tablets are not recommended for administration to children under 2 years of age. For children taking THEOPHYLLINE 300 GDC tablets, NUELIN LIQUID may be considered as an alternative.
What Theophylline 300 GDC contains
Theophylline (anhydrous) 300 mg/tablet.
other ingredients
Sugar Free. Guar gum, magnesium stearate.
Therapeutic classification
R03DA04.
© 2026 SAHPRA. ALL RIGHTS RESERVED